Advertisement
ALC vs BSX
Which Stock Would AI Choose? Alcon (ALC) vs. Boston Scientific (BSX) Stock Comparison
Key Takeaways
- ALC has raised its 2026 profitability outlook twice this year, supported by strong new product launches and a reduced tariff impact.
- BSX has lowered its full-year 2026 sales and earnings guidance amid a cybersecurity disruption, product recalls, and competitive pressure.
- Alcon's recent stock behavior reflects improving margins and momentum, while Boston Scientific's shares have faced a multi-month pullback.
- The two companies operate in different medical segments: Alcon focuses on eye care, while Boston Scientific spans cardiovascular and MedSurg devices.
- Relative performance and market positioning currently favor Alcon on trend consistency, though BSX retains a larger scale and a deep pipeline.
Introduction
Investors weighing healthcare exposure often compare companies with strong recurring demand but very different risk profiles. This stock comparison examines ALC (Alcon Inc.), a global leader in eye care, and BSX (Boston Scientific Corporation), a major medical device maker. Both generate durable revenue from medical procedures, yet their recent relative performance has diverged. Growth-oriented traders may find this comparison useful for assessing momentum and catalysts, while longer-term investors can evaluate business-model resilience, pipeline strength, and valuation. The following sections review each company's recent developments, market positioning, and the factors an AI-driven system would weigh when choosing between them.
ALC Overview and Recent Performance
Alcon is a Swiss-American eye care company whose portfolio spans two segments: Surgical (implantables, consumables, and equipment) and Vision Care (contact lenses and ocular health). Recent market activity has been constructive, with the company reporting second-quarter 2026 net sales of approximately $2.78 billion, up about 7–8% on a reported basis, and core diluted earnings per share (EPS) that beat consensus estimates.
Sentiment has been shaped by several developments in recent weeks. Alcon raised its 2026 core diluted EPS growth guidance to 12–15% and lifted its core operating margin outlook, partly reflecting a roughly $60 million anticipated U.S. tariff refund that reduced its estimated annual tariff impact. New product momentum—including the Unity surgical platform, PanOptix Pro intraocular lenses, and the Tryptyr and Systane dry-eye franchise—has supported revenue growth. Offsetting these positives, the company took a non-cash charge tied to discontinuing its PowerVision accommodating lens program, and implantables continue to face competitive pressure.
BSX Overview and Recent Performance
Boston Scientific is a diversified medical device company that recently reorganized its businesses into two reportable segments: Cardiovascular and MedSurg. Its portfolio includes electrophysiology, structural heart, endoscopy, urology, and neuromodulation products. In the first quarter of 2026, the company reported net sales of roughly $5.20 billion, up about 11.6% year over year, with adjusted EPS of $0.80.
However, recent market activity has been more challenging. Boston Scientific lowered its full-year 2026 growth and earnings guidance, citing a cybersecurity incident, a series of voluntary product recalls across multiple devices, and heightened competition in key categories such as electrophysiology. Management has signaled a path toward restoring shipping and normalizing operations, and the company completed a $2 billion accelerated share repurchase agreement (ASR) in 2026. Despite a broad pipeline—including the pending Penumbra acquisition—the stock has underperformed over the past several months as analysts trimmed price targets and earnings estimates.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively monitor and trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and set of covered securities. Because market conditions change constantly, only a small subset of these bots is well suited to the current environment at any given time. Tickeron's Trending AI Robots page highlights this curated selection, showcasing the bots whose recent performance and strategy alignment stand out. The page offers traders a way to browse bots with varying risk profiles and historical results, from short-term signals to longer-horizon strategies. To explore which AI-driven approaches are currently leading, visit the Trending AI Robots page.
Head-to-Head Comparison
The most notable contrast between these two stocks lies in momentum and operating trends. Alcon has demonstrated improving profitability and consistent product-led growth, with margin expansion and a lighter tariff burden. Boston Scientific, by contrast, is navigating operational disruptions and estimate reductions even though its underlying end-market demand remains healthy.
On scale, Boston Scientific is the larger business, with annual revenue well above Alcon's and a broader reach across multiple high-growth device categories. Its diversified MedSurg and cardiovascular franchises reduce reliance on any single procedure type, though recent recalls and competition have created near-term headwinds. Alcon's narrower eye-care focus offers less diversification but more visible momentum from its premium intraocular lens and dry-eye portfolios.
Risk factors also differ. Alcon carries exposure to tariff policy and a competitive implantables market, while Boston Scientific faces cyber-related disruptions, recall management, and competitive resets in electrophysiology. In terms of market sentiment, Alcon has benefited from repeated guidance increases, whereas Boston Scientific has seen downward estimate revisions and a lower Zacks Rank in recent periods.
Tickeron AI Verdict
Based on observable trend consistency, relative performance, and catalyst clarity, Tickeron's AI would likely favor ALC over BSX in the current environment. Alcon's repeated upward revisions, improving margins, and strong product launches point to a more stable and constructive trend, while Boston Scientific's guidance reductions and operational disruptions weigh on near-term positioning. That said, this is a probabilistic assessment rather than a definitive prediction. Boston Scientific's larger scale, diversified pipeline, and depressed valuation could support a recovery if execution stabilizes, making it a higher-risk, potentially higher-reward scenario that AI models would monitor closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALC is a StrongBuy and BSX is a StrongBuy.
ALC in upward trend: price rose above 50-day moving average on October 22, 2026
ALC moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 23 of 33 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ALC as a result. In 61 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for ALC just turned positive on October 09, 2026. Looking at past instances where ALC's MACD turned positive, the stock continued to rise in 28 of 53 cases over the following month. The odds of a continued upward trend are 53%.
Following a +5.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALC advanced for three days, in 181 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ALC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALC entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. ALC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.509) is normal, around the industry mean (4.961). P/E Ratio (51.083) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (1.165) is also within normal values, averaging (4.143). Dividend Yield (0.015) settles around the average of (0.005) among similar stocks. P/S Ratio (2.996) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Momentum Indicator for BSX turns positive, indicating new upward trend
BSX saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 54 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 61%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BSX's RSI Indicator exited the oversold zone, 15 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 58%.
The Moving Average Convergence Divergence (MACD) for BSX just turned positive on October 12, 2026. Looking at past instances where BSX's MACD turned positive, the stock continued to rise in 25 of 44 cases over the following month. The odds of a continued upward trend are 57%.
BSX moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 199 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BSX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. BSX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.587) is normal, around the industry mean (2.874). P/E Ratio (17.876) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ALC | BSX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 15 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 97 | |
SMR RATING 1..100 | 88 | 55 | |
PRICE GROWTH RATING 1..100 | 56 | 62 | |
P/E GROWTH RATING 1..100 | 10 | 94 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALC's Valuation (69) in the Hospital Or Nursing Management industry is in the same range as BSX (72) in the Medical Specialties industry. This means that ALC’s stock grew similarly to BSX’s over the last 12 months.
BSX's Profit vs Risk Rating (97) in the Medical Specialties industry is in the same range as ALC (100) in the Hospital Or Nursing Management industry. This means that BSX’s stock grew similarly to ALC’s over the last 12 months.
BSX's SMR Rating (55) in the Medical Specialties industry is somewhat better than the same rating for ALC (88) in the Hospital Or Nursing Management industry. This means that BSX’s stock grew somewhat faster than ALC’s over the last 12 months.
ALC's Price Growth Rating (56) in the Hospital Or Nursing Management industry is in the same range as BSX (62) in the Medical Specialties industry. This means that ALC’s stock grew similarly to BSX’s over the last 12 months.
ALC's P/E Growth Rating (10) in the Hospital Or Nursing Management industry is significantly better than the same rating for BSX (94) in the Medical Specialties industry. This means that ALC’s stock grew significantly faster than BSX’s over the last 12 months.
| ALC | BSX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 71% | 1 day ago 58% |
| Stochastic ODDS (%) | 1 day ago 49% | 1 day ago 45% |
| Momentum ODDS (%) | 1 day ago 67% | 1 day ago 61% |
| MACD ODDS (%) | 1 day ago 53% | 1 day ago 57% |
| TrendWeek ODDS (%) | 1 day ago 58% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 57% | 1 day ago 56% |
| Advances ODDS (%) | 8 days ago 57% | 3 days ago 59% |
| Declines ODDS (%) | 4 days ago 56% | 9 days ago 54% |
| BollingerBands ODDS (%) | 1 day ago 66% | 1 day ago 45% |
| Aroon ODDS (%) | 1 day ago 58% | 1 day ago 66% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALC’s FA Score shows that 1 FA rating(s) are green while BSX’s FA Score has 0 green FA rating(s).
- ALC’s FA Score: 1 green, 4 red.
- BSX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALC’s TA Score shows that 4 TA indicator(s) are bullish while BSX’s TA Score has 4 bullish TA indicator(s).
- ALC’s TA Score: 4 bullish, 4 bearish.
- BSX’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALC (@Pharmaceuticals: Other) experienced а +6.08% price change this week, while BSX (@Medical/Nursing Services) price change was +4.24% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.59%. For the same industry, the average monthly price growth was -3.91%, and the average quarterly price growth was +7.47%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.
Reported Earning Dates
ALC is expected to report earnings on Nov 10, 2026.
BSX is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.59% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-1.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
ALC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALC has been loosely correlated with SYK. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALC jumps, then SYK could also see price increases.
BSX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BSX has been closely correlated with ISRG. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BSX jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To BSX | 1D Price Change % | ||
|---|---|---|---|---|
| BSX | 100% | +3.37% | ||
| ISRG - BSX | 71% Closely correlated | +3.67% | ||
| MMSI - BSX | 56% Loosely correlated | +2.78% | ||
| ALC - BSX | 49% Loosely correlated | +4.75% | ||
| MDT - BSX | 46% Loosely correlated | +3.83% | ||
| NTRA - BSX | 45% Loosely correlated | -2.91% | ||
More | ||||